吡柔比星用于非肌层浸润性膀胱癌的临床效果研究

Clinical effect of the pirarubicin in the treatment of non-muscle invasive bladder cancer

目的 研究吡柔比星和羟基喜树碱分别用于非基层浸润性膀胱癌手术后膀胱灌注化疗的有效性和安全性.方法 选取2010年2月至2014年10月到本院就诊并在本院接受治疗的膀胱癌患者共120例作为研究对象.随机分为两组,分别为实验组和对照组,所有患者均采用手术的方式进行治疗,手术后实验组采用羟基喜树碱进行化疗,对照组则采用吡柔比星进行化疗.比较两组的VEGF水平、治疗并发症以及远期复发情况.结果 手术后和用药1周后两组患者的VEGF水平差异无统计学意义,用药8周和用药6个月时,实验组患者的VEGF水平小于对照组,且灌注次数的增加,患者的VEGF水平在逐渐下降,实验组的消化道不良反应的发生率高于对照组（P＜0.05）;而两组在膀胱刺激征、血尿、肝肾功能损伤以及皮疹等方面的差异无统计学意义（P＞0.05）.实验组的远期复发率低于对照组,差异具有统计学意义（P＜0.05）.结论 吡柔比星和羟基喜树碱用于非肌层浸润性膀胱癌的治疗效果较好,吡柔比星的胃肠道不良反应较多,但是远期疗效较好,因此在选择化疗药物时可以根据患者的实际情况进行选择.

Objectives To compare the efficacy and safety of pirarubicin and hydroxycamptothecin（HCPT） combined with intravesical instillation therapy in the treatment of patients with non-muscle invasive bladder cancer.Methods A total of 120 cases of bladder cancer in our hospital from February 2010 to October 2014 were selected as the subjects in this study.All patients were randomly divided into the experimental group and control group.After the operation,the patients in the experimental group were given chemotherapy with hydroxycamptothecin,and patients in the control group were treated with pirarubicin.VEGF levels,treatment complications,and long-term recurrence of the two groups were compared.Results After surgery and medication after 1 week,there was no statistical significant difference in the VEGF level between the two groups,The level of VEGF of the experimental group was less than the control group,and the incidence rate of gastrointestinal adverse reaction of the experimental group was higher than that of control group for 8 weeks and 6 months after treatment （P 〈 0.05）.There was no statistically significant difference in bladder irritation sign,blood in the ufine,liver and kidney function damage and rash between the two groups （P 〉 0.05） The long-term recurrence rate of the experimental group was lower than that of the control group （P 〈 0.05）.Conclusions Pirarubicin and hydroxycamptothecin for non muscle invasive bladder cancer are better.The side-effects of pirarubicin are mostly light and better long-term efficacy.So we should choose the proper chemotherapy drugs in accordance with patients＆#39; individual situation.